Comparative Pharmacology
Head-to-head clinical analysis: SULFACETAMIDE SODIUM versus SULFAMYLON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFACETAMIDE SODIUM versus SULFAMYLON.
SULFACETAMIDE SODIUM vs SULFAMYLON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitively inhibits dihydropteroate synthase, blocking folic acid synthesis in susceptible bacteria.
Sulfamylon (mafenide acetate) is a synthetic sulfonamide that exerts bacteriostatic activity against a wide range of Gram-negative and Gram-positive organisms. It acts by inhibiting the enzyme dihydropteroate synthase, which is involved in folate synthesis, thereby blocking bacterial DNA replication. Additionally, it may be bactericidal at high concentrations via inhibition of cell wall synthesis.
1-2 drops of 10-30% solution into the conjunctival sac every 2-3 hours initially, tapering as infection resolves. Ointment: 0.5-inch ribbon into conjunctival sac every 3-4 hours and at bedtime.
Topical: Apply a thin layer to the wound once or twice daily. Maximum coverage area should not exceed body surface area of 20%.
None Documented
None Documented
7-12.8 hours (prolonged in renal impairment; requires dosing adjustment in CrCl <50 mL/min).
The terminal elimination half-life is approximately 7-8 hours in patients with normal renal function. In renal impairment, half-life may be prolonged, requiring dosing adjustments.
Renal: 85-95% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: <5%.
Primarily renal excretion as unchanged drug and its metabolite; approximately 87% of a dose is recovered in urine within 24 hours as sulfacetamide and its deacetylated metabolite, with about 10% as unchanged drug. Less than 2% is excreted in feces.
Category A/B
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic